Pharmaceutical products

Tender description

NHS National Pharmaceuticals Transition 2019_2 Offer reference number: CM/PHG/17/5548 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 42 months. Potential periods of call-offs under the framework agreement: — NWLN: 1.2.2020 to 30.9.2020 (8 months), — LSNE: 1.2.2020 to 28.2.2021 (13 months), — CESW: 1.2.2020 to 31.10.2021 (21 months). Products on the framework include (but are not limited to): — Azacitadine, — Colesevelam hcl, — Deferiprone, — Ezetimibe + simvastatin, — Fosamprenavir calcium, — Lopinavir + ritonavir, — Oxybutinin patches, — Parecoxib, — Posaconazole, — Roflumilast, — Sodium oxybate, — Vildagliptin + metformin, — Vinflunine ditartrate, — Vinorelbine (oral). NHS National Pharmaceuticals Transition 2019_2 Offer reference number: CM/PHG/17/5548 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 42 months. Potential periods of call-offs under the framework agreement: — NWLN: 1.2.2020 to 30.9.2020 (8 months), — LSNE: 1.2.2020 to 28.2.2021 (13 months), — CESW: 1.2.2020 to 31.10.2021 (21 months). NHS National Pharmaceuticals Transition 2019_2 Offer reference number: CM/PHG/17/5548 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 42 months. Potential periods of call-offs under the framework agreement: — NWLN: 1.2.2020 to 30.9.2020 (8 months), — LSNE: 1.2.2020 to 28.2.2021 (13 months), — CESW: 1.2.2020 to 31.10.2021 (21 months). NHS National Pharmaceuticals Transition 2019_2 Offer reference number: CM/PHG/17/5548 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 42 months. Potential periods of call-offs under the framework agreement: — NWLN: 1.2.2020 to 30.9.2020 (8 months), — LSNE: 1.2.2020 to 28.2.2021 (13 months), — CESW: 1.2.2020 to 31.10.2021 (21 months).